HUE054399T2 - Vegyületek viszketéses állapotok kezelésére - Google Patents
Vegyületek viszketéses állapotok kezeléséreInfo
- Publication number
- HUE054399T2 HUE054399T2 HUE16784019A HUE16784019A HUE054399T2 HU E054399 T2 HUE054399 T2 HU E054399T2 HU E16784019 A HUE16784019 A HU E16784019A HU E16784019 A HUE16784019 A HU E16784019A HU E054399 T2 HUE054399 T2 HU E054399T2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- pruritic conditions
- treating pruritic
- treating
- conditions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001823 pruritic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151618P | 2015-04-23 | 2015-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054399T2 true HUE054399T2 (hu) | 2021-09-28 |
Family
ID=57144302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16784019A HUE054399T2 (hu) | 2015-04-23 | 2016-04-22 | Vegyületek viszketéses állapotok kezelésére |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9624233B2 (enExample) |
| EP (1) | EP3286198B1 (enExample) |
| JP (1) | JP6744327B2 (enExample) |
| AU (1) | AU2016252892B2 (enExample) |
| CA (1) | CA2981625C (enExample) |
| CY (1) | CY1124163T1 (enExample) |
| DK (1) | DK3286198T3 (enExample) |
| ES (1) | ES2867799T3 (enExample) |
| HR (1) | HRP20210606T1 (enExample) |
| HU (1) | HUE054399T2 (enExample) |
| LT (1) | LT3286198T (enExample) |
| PL (1) | PL3286198T3 (enExample) |
| PT (1) | PT3286198T (enExample) |
| SI (1) | SI3286198T1 (enExample) |
| WO (1) | WO2016172613A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116597A (zh) * | 2018-10-31 | 2020-05-08 | 扬子江药业集团江苏紫龙药业有限公司 | 一种纳布啡游离碱的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4477456A (en) | 1981-07-02 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Octahydro-4A,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline derivatives having analgesic, narcotic antagonist and anorexigenic properties |
| US7195882B2 (en) * | 2003-06-03 | 2007-03-27 | Roche Diagnostics Operations, Inc. | Monoclonal antibodies specific for buprenorphine and metabolites thereof |
| CA2682125C (en) * | 2007-03-29 | 2015-06-16 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| EP2935278B1 (en) * | 2012-12-19 | 2017-03-15 | Novartis AG | Tricyclic compounds for inhibiting the cftr channel |
-
2016
- 2016-04-22 CA CA2981625A patent/CA2981625C/en active Active
- 2016-04-22 EP EP16784019.8A patent/EP3286198B1/en active Active
- 2016-04-22 WO PCT/US2016/029024 patent/WO2016172613A1/en not_active Ceased
- 2016-04-22 PL PL16784019T patent/PL3286198T3/pl unknown
- 2016-04-22 ES ES16784019T patent/ES2867799T3/es active Active
- 2016-04-22 SI SI201631169T patent/SI3286198T1/sl unknown
- 2016-04-22 DK DK16784019.8T patent/DK3286198T3/da active
- 2016-04-22 LT LTEP16784019.8T patent/LT3286198T/lt unknown
- 2016-04-22 HU HUE16784019A patent/HUE054399T2/hu unknown
- 2016-04-22 PT PT167840198T patent/PT3286198T/pt unknown
- 2016-04-22 AU AU2016252892A patent/AU2016252892B2/en active Active
- 2016-04-22 JP JP2017555210A patent/JP6744327B2/ja active Active
- 2016-04-22 HR HRP20210606TT patent/HRP20210606T1/hr unknown
- 2016-04-22 US US15/136,742 patent/US9624233B2/en active Active
-
2021
- 2021-05-18 CY CY20211100427T patent/CY1124163T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3286198A4 (en) | 2018-09-26 |
| AU2016252892A1 (en) | 2017-10-26 |
| CA2981625A1 (en) | 2016-10-27 |
| EP3286198A1 (en) | 2018-02-28 |
| CA2981625C (en) | 2023-05-23 |
| CY1124163T1 (el) | 2022-05-27 |
| PL3286198T3 (pl) | 2021-09-06 |
| EP3286198B1 (en) | 2021-02-24 |
| HRP20210606T1 (hr) | 2021-05-28 |
| DK3286198T3 (da) | 2021-05-03 |
| SI3286198T1 (sl) | 2021-08-31 |
| AU2016252892B2 (en) | 2019-05-02 |
| US20160311832A1 (en) | 2016-10-27 |
| PT3286198T (pt) | 2021-04-26 |
| LT3286198T (lt) | 2021-07-12 |
| JP2018513174A (ja) | 2018-05-24 |
| US9624233B2 (en) | 2017-04-18 |
| JP6744327B2 (ja) | 2020-08-19 |
| WO2016172613A1 (en) | 2016-10-27 |
| ES2867799T3 (es) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201510019D0 (en) | Compounds | |
| IL254393A0 (en) | Methods for treating diseases associated with pathological changes in protein | |
| IL252716A0 (en) | Anti-csf1r antibodies for the treatment of pvns | |
| GB201508747D0 (en) | Compounds | |
| IL258988A (en) | Methods for treating epilepsy | |
| GB201514754D0 (en) | Compounds | |
| GB201514751D0 (en) | Compounds | |
| IL249475A0 (en) | Methods for treating itching | |
| IL257202B (en) | Compounds useful for ror–gamma–t inhibition | |
| GB201508864D0 (en) | Compounds | |
| GB201510493D0 (en) | Compounds | |
| PT3250218T (pt) | Péptido natkide para o tratamento da obesidade | |
| PT3350149T (pt) | Compostos terminados com[(2-etoxi-5-trans-1-propen-1-il)-fenoxil] | |
| PL3131890T3 (pl) | Związki do leczenia zakażeń wirusowych | |
| EP3130586A4 (en) | Process for treating homoserine-based compound | |
| GB201503926D0 (en) | Compounds | |
| GB201501115D0 (en) | Compounds | |
| LT3286198T (lt) | Junginiai, skirti gydyti niežulio būkles | |
| IL249616A0 (en) | Methods for treating inflammation | |
| EP3246432A4 (en) | Method for treating parts | |
| GB201508857D0 (en) | Compounds | |
| GB201709559D0 (en) | Compounds for treating lupus | |
| GB201516059D0 (en) | Compounds | |
| GB201512279D0 (en) | Compounds | |
| GB201511387D0 (en) | Compounds |